Article
Validation of a next-generation sequencing assay for clinical molecular oncology.
The Journal of molecular diagnostics : JMD - 1 Jan 2014
Cottrell Catherine E, Al-Kateb Hussam, Bredemeyer Andrew J, Duncavage Eric J, Spencer David H, Abel Haley J, Lockwood Christina M, Hagemann Ian S, O'Guin Stephanie M, Burcea Lauren C, Sawyer Christopher S, Oschwald Dayna M, Stratman Jennifer L, Sher Dorie A, Johnson Mark R, Brown Justin T, Cliften Paul F, George Bijoy, McIntosh Leslie D, Shrivastava Savita, Nguyen Tudung T, Payton Jacqueline E, Watson Mark A, Crosby Seth D, Head Richard D, Mitra Robi D, Nagarajan Rakesh, Kulkarni Shashikant, Seibert Karen, Virgin Herbert W, Milbrandt Jeffrey, Pfeifer John D
Abstract excerpt
Currently, oncology testing includes molecular studies and cytogenetic analysis to detect genetic aberrations of clinical significance. Next-generation sequencing (NGS) allows rapid analysis of multiple genes for clinically actionable somatic variants. The WUCaMP assay uses targeted capture for NGS analysis of 25 cancer-associated genes to detect mutations at actionable loci. We present clinical validation of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.